News
- Author:
- Steve Stiles
Publish date: June 22, 2021
That increasing risk, which is independent of oral anticoagulation, may attenuate or disappear in patients who give up drinking after their AF diag...
News
- Author:
- Steve Stiles
Publish date: June 11, 2021
Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-...
News
- Author:
- Steve Stiles
Publish date: May 17, 2021
The program, started in the hospital, worked on capabilities such as mobility, balance, and strength that would be necessary if exercises meant to ...
News
- Author:
- Steve Stiles
Publish date: May 11, 2021
A prespecified patient-focused reassessment of the influential trial based on “days alive out of hospital” saw an...
News
- Author:
- Steve Stiles
Publish date: May 11, 2021
Often tough to tell apart and with surprisingly poor prognoses, type 2 MI and nonischemic myocardial injury lack trials to guide therapy. Whether t...
News
- Author:
- Steve Stiles
Publish date: April 30, 2021
Literally all known 75- and 76-year-olds in two Swedish regions were included, whether or not they were screened by mobile ECG recorder. But does t...
News
- Author:
- Steve Stiles
Publish date: April 15, 2021
A prospective study offers new insights to questions such as why high HDL cholesterol levels aren’t always cardioprotective.
News
- Author:
- Steve Stiles
Publish date: April 13, 2021
The recall applies to implantable defibrillators, with and without resynchronization pacing, that are at apparent risk for premature and possibly r...
News
- Author:
- Steve Stiles
Publish date: February 26, 2021
The strategy seemed to work in this trial: two-thirds of patients who previously rejected statins, perceiving them as the cause of muscle pain, dec...
News
- Author:
- Steve Stiles
Publish date: February 23, 2021
A large survey of type 2 MI, triggered when myocardial oxygen demand outstrips supply, points to confusion hindering its diagnosis and treatment an...
News
- Author:
- Steve Stiles
Publish date: February 17, 2021
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for “chronic heart failure” but almost teasingly adds, “the benefits are ...
News
- Author:
- Steve Stiles
Publish date: February 12, 2021
Indicated for homozygous familial hypercholesterolemia on top of other lipid-modifying therapy, Evkeeza (Regeneron) is a first-in-class inhibitor o...
News
- Author:
- Steve Stiles
Publish date: January 27, 2021
Some supposed ‘myocarditis’ detected by MRI after COVID-19 in university varsity competitors might be normal heart muscle – normal for athletes, th...
News
- Author:
- Steve Stiles
Publish date: January 19, 2021
Together, four “easily measured” biomarkers predicted 5-year heart failure risk in patients with diabetes or prediabetes, potentially identifying b...
News
- Author:
- Steve Stiles
Publish date: December 10, 2020
That future cardiovascular risk tracks closely with plaque burden, but not so much with whether the coronary disease is obstructive, may never have...
